Difference between revisions of "Ibritumomab tiuxetan (Zevalin)"
(Created page with "==General information== Class/mechanism: <ref name="insert">[http://www.zevalin.com/v3/pdf/Zevalin_PI_Website.pdf Ibritumomab (Zevalin) package insert]</ref><ref>[http://hemonc.o...") |
|||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: <ref name="insert">[http://www.zevalin.com/v3/pdf/Zevalin_PI_Website.pdf Ibritumomab (Zevalin) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/ibritumomab.pdf Ibritumomab (Zevalin) package insert (locally hosted backup)]</ref> | + | Class/mechanism: Zevalin is a CD20-directed radiotherapeutic antibody administered as part of |
| + | the Zevalin therapeutic regimen indicated for the treatment of patients with: | ||
| + | |||
| + | Ibritumomab tiuxetan binds specifically to the CD20 antigen (human B-lymphocyte-restricted differentiation antigen, Bp35). The apparent affinity (KD) of ibritumomab tiuxetan for the CD20 antigen ranges between approximately 14 to 18 nM. The CD20 antigen is expressed on pre-B and mature B lymphocytes and on > 90% of B-cell non-Hodgkin’s lymphomas (NHL). The CD20 antigen is not shed from the cell surface and does not internalize upon antibody binding. The chelate tiuxetan, which tightly binds In-111 or Y-90, is covalently linked to ibritumomab. The beta emission from Y- 90 induces cellular damage by the formation of free radicals in the target and neighboring cells. Ibritumomab tiuxetan binding was observed in vitro on lymphoid cells of the bone marrow, lymph node, thymus, red and white pulp of the spleen, and lymphoid follicles of the tonsil, as well as lymphoid nodules of other organs such as the large and small intestines. | ||
| + | |||
| + | <ref name="insert">[http://www.zevalin.com/v3/pdf/Zevalin_PI_Website.pdf Ibritumomab (Zevalin) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/ibritumomab.pdf Ibritumomab (Zevalin) package insert (locally hosted backup)]</ref> | ||
<br>Route: TBD | <br>Route: TBD | ||
<br>Extravasation: TBD | <br>Extravasation: TBD | ||
Revision as of 21:27, 10 February 2012
General information
Class/mechanism: Zevalin is a CD20-directed radiotherapeutic antibody administered as part of the Zevalin therapeutic regimen indicated for the treatment of patients with:
Ibritumomab tiuxetan binds specifically to the CD20 antigen (human B-lymphocyte-restricted differentiation antigen, Bp35). The apparent affinity (KD) of ibritumomab tiuxetan for the CD20 antigen ranges between approximately 14 to 18 nM. The CD20 antigen is expressed on pre-B and mature B lymphocytes and on > 90% of B-cell non-Hodgkin’s lymphomas (NHL). The CD20 antigen is not shed from the cell surface and does not internalize upon antibody binding. The chelate tiuxetan, which tightly binds In-111 or Y-90, is covalently linked to ibritumomab. The beta emission from Y- 90 induces cellular damage by the formation of free radicals in the target and neighboring cells. Ibritumomab tiuxetan binding was observed in vitro on lymphoid cells of the bone marrow, lymph node, thymus, red and white pulp of the spleen, and lymphoid follicles of the tonsil, as well as lymphoid nodules of other organs such as the large and small intestines.
[1][2]
Route: TBD
Extravasation: TBD
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].
Patient drug information
- Ibritumomab (Zevalin) patient drug information (Chemocare)[3]
- Ibritumomab (Zevalin) patient drug information (UpToDate)[4]